Jeana Keough's Tongue Cancer: Early Signs, Causes, and Modern Treatment Pathways

Jeana Keough's Tongue Cancer: Early Signs, Causes, and Modern Treatment Pathways

Quick Answer: Tongue cancer is a malignant squamous cell growth in the oral cavity that presents with persistent ulcers, lumps, or localized oral pain. Treatment requires a coordinated multidisciplinary team, combining surgical resection, neck dissection, reconstruction, and adjuvant chemoradiotherapy, to clear malignant cells while protecting speech and swallowing function.

Key Takeaways:

• Oral tongue malignancies frequently mimic benign dental irritation or canker sores (aphthous ulcers), delaying detection until regional lymph nodes become involved.
• Any oral ulcer, red patch (erythroplakia), or white plaque (leukoplakia) persisting longer than three weeks requires prompt clinical evaluation and a tissue biopsy.
• Chronic tobacco use, heavy alcohol consumption, and human papillomavirus (HPV) infection serve as the primary oncogenic drivers of tongue neoplasms.
• Advanced disease management incorporates microvascular free-flap reconstruction, intensity-modulated radiation therapy (IMRT), platinum-based chemotherapy, and targeted checkpoint immunotherapy.
• Dedicated speech-language pathology and swallowing therapy help restore oral intake, clear speech, and long-term daily independence.

Tongue cancer is a head and neck malignancy defined by the uncontrolled growth of abnormal epithelial cells, predominantly squamous cell carcinoma, affecting the front two-thirds (oral tongue) or the base of the tongue (posterior one-third). Representing one of the most common oral cavity cancers, it requires prompt histopathologic diagnosis and precise anatomical staging to control primary tumor invasion and prevent spread into neck lymph nodes.

Jeana Keough's Diagnosis: How a Persistent Sore Spot Revealed Tongue Cancer

Tongue cancer often presents subtly as localized oral discomfort, which former Real Housewives of Orange County star Jeana Keough initially attributed to a problematic tooth before medical evaluation at age 70 confirmed squamous cell carcinoma that had spread to regional lymph nodes.

Keough shared details of her diagnosis in 2026, describing an insidious onset where a localized sore spot inside her mouth felt like routine dental irritation. Because early neoplastic changes do not always cause severe discomfort, patients frequently consult a dentist before seeing an ear, nose, and throat (ENT) specialist or head and neck surgeon. By the time specialists obtained a definitive tissue biopsy, malignant cells had already migrated into regional cervical lymph nodes. This required two operations to remove the primary oral tumor and clear the affected lymph nodes in her neck.

Her clinical team expanded her plan into multimodal treatment, adding radiation therapy, chemotherapy, and immunotherapy to reduce recurrence risks. Public updates shared by her daughter in October 2026 noted her progress through these therapies alongside active physical and nutritional rehabilitation. Keough's experience shows why persistent tongue cancer symptoms demand formal tissue evaluation rather than repeated dental adjustments.

Several clinical factors explain why primary oral lesions are so frequently confused with benign oral conditions:

• Anatomical proximity to lower molars: Lesions along the side edge of the tongue sit directly against dental cusps. Patients often assume the pain stems from accidental biting, sharp enamel, or poorly fitted bridges.
• Intermittent symptom intensity: Early-stage malignancies can cause fluctuating discomfort, temporarily mimicking minor aphthous ulcers that seem to resolve.
• Absence of early nerve pain: Superficial squamous cell carcinomas rarely cause severe pain until they invade deep tongue muscle or the lingual nerve.

Early Signs and Appearance: What Does Tongue Cancer Look Like?

Early tongue cancer typically appears as a persistent red patch (erythroplakia), white plaque (leukoplakia), firm lump, or non-healing ulcer lasting longer than three weeks, most often along the side edge of the tongue.

Patients evaluating oral changes often ask what does tongue cancer look like during its earliest stages. Unlike self-limiting oral ulcers, malignant lesions feel indurated, meaning they have a noticeable firmness when felt between gloved fingers, and show raised, rolled, or poorly defined borders. The mucosal surface may look smooth, speckled, granular, or deeply cratered, with fragile tissue that bleeds easily during brushing or chewing.

The lateral border of the oral tongue accounts for most oral tongue cancers, followed by the underside (ventral surface) and the adjacent floor of the mouth. In contrast, base-of-tongue malignancies originate behind the terminal sulcus in the throat (oropharynx). They remain visually hidden during routine self-examination and often present first as a painless neck lump or swallowing difficulty (dysphagia).

Feature	Benign Aphthous Ulcer (Canker Sore)	Tongue Squamous Cell Carcinoma
Duration	Resolves spontaneously in 7 to 14 days	Persists beyond 3 weeks without healing
Margin & Contour	Flat, well-circumscribed erythematous halo	Rolled, raised, everted, or irregular borders
Tissue Texture	Soft, pliable surrounding mucosal tissue	Indurated, firm, hardened base on palpation
Surface Morphology	Shallow, yellow-gray fibrinous slough	Heterogeneous red patch, white plaque, or ulcer
Contact Bleeding	Rare; minimal bleeding with light contact	Frequent; friable tissue bleeds readily
Regional Lymph Nodes	Soft, tender, transient reactive lymphadenopathy	Firm, non-tender, fixed, persistent cervical mass

Causes and Risk Factors: How Do You Get Tongue Cancer?

Tongue cancer develops when squamous epithelial cells acquire genetic mutations driven primarily by tobacco use, frequent alcohol consumption, persistent mucosal trauma, and human papillomavirus (HPV) infection, particularly HPV-16 at the tongue base.

When addressing how do you get tongue cancer, clinicians examine both external carcinogen exposure and patient-specific cellular vulnerabilities. Carcinogenesis in the oral cavity follows a multistep model: chronic exposure to environmental toxins triggers progressive mutations in key cell-cycle genes, particularly TP53 and CDKN2A. Over time, these mutations allow dysplastic keratinocytes to bypass normal cell death, multiply unchecked, and breach the basement membrane.

Tobacco and alcohol have a well-documented synergistic effect on oral tissues. Ethanol acts as a solvent, increasing mucosal permeability so tobacco carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons, can penetrate vulnerable basal cells. While traditional oral tongue cancer predominantly affects older adults with tobacco and alcohol exposure, clinicians also diagnose it in younger adults without these risks. In these patients, genetic factors, chronic mechanical irritation, or immune alterations remain under active study.

Established risk factors for oral and base-of-tongue cancers include:

• Smoked and smokeless tobacco: Cigarettes, cigars, pipes, and chewing tobacco deliver concentrated carcinogens directly to the tongue surface.
• Regular alcohol consumption: Heavy alcohol intake irritates oral membranes independently and multiplies tobacco-related cancer risks.
• High-risk HPV infection: Strains HPV-16 and HPV-18 drive oncogenesis through viral oncoproteins E6 and E7, primarily targeting the lymphoid tissue at the base of the tongue.
• Chronic mechanical trauma: Sharp, fractured teeth or ill-fitting dental prostheses cause ongoing mucosal injury and repeated repair cycles.
• Immunosuppression: Long-term immunosuppressive medication or systemic immune deficits weaken baseline cellular DNA repair.

Clinical Staging: Assessing Tumor Extent and Tongue Cancer Stage Four

Clinicians confirm tongue cancer through a tissue biopsy and cross-sectional imaging (CT, MRI, PET), categorizing disease extent from localized stage I lesions to tongue cancer stage four, which indicates deep muscle invasion, extensive neck lymph node involvement, or distant spread.

Diagnostic evaluation begins with an incisional or punch biopsy performed under local anesthesia to obtain a definitive tissue sample. Pathologists confirm squamous cell carcinoma, evaluate tumor differentiation, and check for spread along nerves (perineural invasion) or into blood and lymphatic vessels (lymphovascular invasion). Imaging studies, including contrast-enhanced magnetic resonance imaging (MRI) and computed tomography (CT) scans, measure local tissue depth and inspect neck lymph nodes for enlargement or central breakdown.

Staging follows the American Joint Committee on Cancer (AJCC) TNM framework, which evaluates primary tumor size and depth of invasion (DOI), regional lymph node status, and distant metastasis. Depth of invasion measures how deeply cancer cells penetrate beneath the basement membrane into the intrinsic tongue muscles. An invasion depth exceeding 4 to 5 millimeters significantly raises the risk of occult lymph node involvement. This finding often warrants surgical staging of the neck even if initial imaging shows no enlargement.

Stage	Primary Tumor & Depth of Invasion (DOI)	Regional Lymph Node Involvement (N)	Distant Spread (M)
Stage I	Tumor ≤ 2 cm across; DOI ≤ 5 mm	No lymph node involvement (N0)	No distant spread (M0)
Stage II	Tumor ≤ 2 cm with DOI 5-10 mm, or 2-4 cm with DOI ≤ 10 mm	No lymph node involvement (N0)	No distant spread (M0)
Stage III	Tumor > 4 cm or DOI > 10 mm; or smaller tumor with single node ≤ 3 cm	Single ipsilateral node ≤ 3 cm (N1), or N0	No distant spread (M0)
Stage IVA	Tumor invades cortical bone, deep extrinsic muscle, or multiple regional nodes	Multiple ipsilateral, contralateral, or bilateral nodes ≤ 6 cm (N2)	No distant spread (M0)
Stage IVB	Tumor invades skull base or wraps carotid artery; or any node > 6 cm or showing extranodal extension	Extensive nodal disease (N3) or inoperable primary tumor	No distant spread (M0)
Stage IVC	Any tumor dimensions or depth of invasion	Any nodal status	Distant metastasis present (M1: lung, bone, liver)

A diagnosis of tongue cancer stage four does not automatically indicate a terminal illness. Stages IVA and IVB represent locally or regionally advanced disease that oncology teams still treat with curative intent. Stage IVC signifies distant organ metastasis, which requires systemic therapy to manage.

Comprehensive Tongue Cancer Treatment: Surgery, Radiation, Chemotherapy, and Immunotherapy

Standard tongue cancer treatment for locally advanced disease requires a multimodal approach combining surgical resection (partial glossectomy and neck dissection) with adjuvant external beam radiotherapy, platinum-based chemotherapy, and systemic immunotherapy targeting immune checkpoint pathways.

Surgical resection serves as the primary curative approach for oral tongue cancer. Head and neck oncologists perform a partial, hemilateral, or subtotal glossectomy to remove the tumor with a margin of healthy tissue, aiming for clear microscopic margins of at least 5 millimeters. Concurrently, a selective or modified radical neck dissection removes cervical lymph node stations (typically levels I through III or IV) to clear micrometastases and stage the neck accurately.

Adjuvant therapies depend on the final surgical pathology report. If the excised tissue shows high-risk features, such as positive surgical margins, multi-station nodal involvement, or extranodal extension (where cancer cells break through the lymph node capsule into surrounding fat), adjuvant treatment is recommended to reduce recurrence risk.

Key modalities in modern tongue cancer treatment include:

• Surgical Excision (Glossectomy): Complete removal of the tongue tumor with verified clear margins, designed to preserve as much mobile tongue tissue as possible.
• Lymph Node Removal (Neck Dissection): Systematic excision of cervical lymph node groups to identify and remove regional tumor spread.
• Intensity-Modulated Radiation Therapy (IMRT): Advanced external beam radiation that shapes beams around tumor beds and nodal basins while sparing salivary glands, the jawbone, and the spinal cord.
• Platinum-Based Chemotherapy: Intravenous cisplatin or carboplatin given concurrently with radiation to make cancer cells more sensitive to radiotherapy, improving regional tumor control.
• Immune Checkpoint Inhibitors: Monoclonal antibodies targeting PD-1 (such as pembrolizumab or nivolumab) used for recurrent or metastatic squamous cell disease that does not respond to standard locoregional therapy.

Functional Recovery: Managing Speech, Swallowing, and Nutrition After Tongue Resection

Recovery after tongue surgery centers on speech-language pathology, swallowing therapy, and structured nutritional support, often using temporary feeding tubes and free-flap tissue reconstruction, to rebuild oral motor control and swallowing safety.

Removing part of the tongue alters the oral phase of swallowing and affects articulation. To reduce functional disability after substantial tissue loss, reconstructive surgeons perform microvascular free-flap transfers during the main operation. Surgeons harvest vascularized tissue from a donor site, such as the forearm (radial forearm free flap) or thigh (anterolateral thigh flap), and connect its small blood vessels to neck vessels under a microscope, restoring volume and mobility to the tongue and floor of the mouth.

Structured rehabilitation progresses across multiple distinct phases:

1. Immediate Postoperative Protection (Days 1 to 7): Clinicians monitor free-flap blood supply, safeguard the airway (sometimes using a temporary protective tracheostomy), and provide nutrition through a nasogastric or stomach (gastrostomy) feeding tube.
2. Early Swallowing Assessment (Weeks 2 to 6): Speech-language pathologists perform fiberoptic endoscopic evaluations of swallowing (FEES) or videofluoroscopic swallowing studies (VFSS) to check for silent aspiration before introducing soft foods and liquids.
3. Targeted Motor Therapy (Weeks 4 to 12): Targeted swallowing exercises strengthen remaining muscle fibers to move food safely toward the esophagus and protect the airway.
4. Speech Articulation Training (Months 2 to 6): Therapists guide compensatory tongue movements to improve clarity for speech sounds like "t," "d," "s," and "l" that rely on contact with the roof of the mouth.
5. Long-Term Oral Health and Nutrition: Care teams treat radiation-related dry mouth (xerostomia), monitor tissue stiffness, and maintain caloric intake to prevent cancer-related weight loss.

Prognosis and Long-Term Outlook: What Is the Reported Tongue Cancer Survival Rate?

The overall tongue cancer survival rate varies significantly by stage at detection, with national cancer registry data reporting 5-year relative survival rates around 80% to 85% for localized disease, dropping to approximately 40% to 68% when regional lymph nodes are involved.

Registry data from sources like the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program demonstrate that disease stage at diagnosis remains the strongest prognostic factor. When oral tongue squamous cell carcinoma is detected early and removed before it penetrates deep muscle or spreads to lymph nodes, long-term disease control rates are notably favorable.

Regional lymph node spread lowers the reported tongue cancer survival rate significantly, highlighting the importance of timely detection. Pathological indicators such as deep muscle invasion (> 10 mm), extranodal extension, and positive surgical margins increase recurrence risks and require postoperative chemoradiation. Conversely, oropharyngeal and base-of-tongue tumors linked to high-risk HPV infection generally respond better to radiation and systemic therapies, showing more favorable survival rates than HPV-negative cancers associated primarily with heavy smoking and alcohol use.

Survival statistics represent historical population averages and cannot predict an individual patient's outcome. Age, overall health, access to multidisciplinary cancer teams, reconstructive outcomes, and adherence to regular follow-up visits all influence recovery and long-term disease control.

Potential Complications and Surgical Risks of Tongue Cancer Therapy

Treating tongue cancer carries inherent surgical and radiation-related risks, including microvascular flap compromise, secondary bleeding, wound breakdown, chronic swallowing difficulty, radiation-induced tooth decay, and osteoradionecrosis of the jawbone.

Surgical intervention carries risks specific to head and neck anatomy. Microvascular free flaps develop arterial or venous blood clots in approximately 2% to 5% of operations, requiring emergency re-exploration to salvage the transferred tissue. A hematoma in the neck can compress the airway and demands prompt drainage. Inadvertent injury to nearby nerves, such as the hypoglossal nerve (tongue movement), lingual nerve (tongue sensation), or the marginal mandibular branch of the facial nerve (lower lip movement), can cause temporary or long-term weakness or numbness.

Radiation therapy introduces known regional side effects:

• Severe oral mucositis: Painful mouth sores develop during radiation, often requiring prescription pain relief and temporary reliance on a feeding tube.
• Dry mouth (xerostomia): Reduced salivary gland function causes persistent dry mouth, difficulty swallowing dry foods, and rapid dental decay.
• Radiation caries and jawbone damage (osteoradionecrosis): Radiation weakens the blood supply to the lower jaw (mandible). Tooth extractions in irradiated areas without preventive measures can lead to non-healing bone exposure.
• Neck tissue stiffness (fibrosis): Radiation can stiffen neck and throat muscles, causing jaw stiffness (trismus) and long-term swallowing limitations.

Patients undergoing active cancer therapy should seek immediate emergency medical care for sudden difficulty breathing, heavy oral bleeding, new neck swelling, inability to swallow liquids, or a fever above 100.4°F (38°C) during chemotherapy.

Frequently Asked Questions

Is tongue cancer treatable?

Yes, tongue cancer is treatable, with high rates of long-term disease control when doctors identify and treat it at an early stage. Surgical excision combined with lymph node evaluation forms the foundation of curative care. For advanced or high-risk cases, teams combine surgery with radiation therapy, chemotherapy, or immunotherapy. Comprehensive swallowing and speech therapy helps preserve articulation and oral function over the long term.

What are the earliest physical warning signs of tongue cancer?

The earliest warning sign is typically a persistent ulcer, lump, or red or white patch along the side of the tongue that does not heal within three weeks. Other early signs include localized numbness, unexplained bleeding, or a constant sensation that a tooth is rubbing against an irritated patch of tissue.

Why does tongue cancer spread to the neck lymph nodes so quickly?

The tongue has a dense, highly interconnected network of lymphatic vessels and an abundant blood supply. Continuous muscular movement during speaking and swallowing circulates tissue fluid through these lymphatic pathways, allowing invasive cancer cells to reach cervical lymph nodes relatively early in disease progression.

How does base-of-tongue cancer differ from oral tongue cancer?

Oral tongue cancer develops on the mobile front two-thirds of the tongue, where it is easily visible and accessible during a routine dental or medical examination. Base-of-tongue cancer arises in the back third of the tongue within the throat (oropharynx), where it remains hidden from direct view, is frequently linked to HPV infection, and often presents first as a painless neck lump rather than an obvious mouth lesion.